Washington is currently home to 1730 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Seattle, Spokane, Tacoma and Vancouver. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of GS-4528 in Adults With Solid Tumors
NCT05840224
Recruiting
The goals of this clinical study are to identify if GS-4528 alone or in combination with anti-programmed cell death protein 1 (PD-1) (Anti-PD-1) Monoclonal Antibody is safe and tolerable in people with solid tumors and to identify the recommended dose of GS-4528 for further development that is safe to give to people alone or in combination with Anti-PD-1 Monoclonal Antibody. The primary objectives of this study are: * To assess the safety and tolerability of GS-4528 as monotherapy and in combi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/10/2025
Locations: The University of Washington/FHCC, Seattle, Washington
Conditions: Solid Tumor
Register for Updates
Optimizing Tracheal Intubation Outcomes and Neonatal Safety
NCT05838690
Recruiting
The purpose of the study is to assess the impact of a personalized intubation planning tool, the Personalized INtubation Safety (PINS) Bundle on intubation procedural safety and clinical outcomes among patients intubated in the neonatal intensive care unit (NICU) setting.
Gender:
ALL
Ages:
1 year and below
Trial Updated:
06/10/2025
Locations: University of Washington, Seattle, Washington
Conditions: Infant, Intubation Complication
Register for Updates
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
NCT05065372
Recruiting
Diabetic kidney disease and cardiovascular disease remain the leading causes of morbidity and mortality in people with type 1 diabetes and are exacerbated with longer duration of diabetes and time outside goal glycemic range. Yet, type 1 diabetes is a complex disease with pathophysiology that extends beyond beta-cell injury and insulin deficiency to include insulin resistance and renal vascular resistance, factors that accelerate cardiovascular disease risk. We have shown that metformin improved... Read More
Gender:
ALL
Ages:
Between 12 years and 25 years
Trial Updated:
06/10/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
Register for Updates
Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study
NCT04949464
Recruiting
This clinical trial evaluates the usefulness of using a smartphone-based HIV-specific smoking cessation intervention at the time of lung cancer screening in helping people living with HIV quit smoking. Positively Smoke Free - Mobile may help patients with HIV quit smoking.
Gender:
ALL
Ages:
Between 45 years and 80 years
Trial Updated:
06/10/2025
Locations: Virginia Mason Medical Center, Seattle, Washington
Conditions: HIV Infection, Tobacco-Related Carcinoma
Register for Updates
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT03488693
Recruiting
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Gender:
FEMALE
Ages:
35 years and above
Trial Updated:
06/10/2025
Locations: MultiCare Auburn Medical Center, Auburn, Washington
Conditions: Breast Cancer
Register for Updates
ColoCare Study - Colorectal Cancer Cohort
NCT02328677
Recruiting
ColoCare is an international prospective cohort study of stage I-IV colorectal cancer patients (ICD-10 C18-C20).
Gender:
ALL
Ages:
Between 18 years and 89 years
Trial Updated:
06/10/2025
Locations: FHCRC, Seattle, Washington
Conditions: Colorectal Cancer
Register for Updates
To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome
NCT06840496
Recruiting
Primary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective • To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and women with Rett syndrome
Gender:
FEMALE
Ages:
Between 5 years and 20 years
Trial Updated:
06/09/2025
Locations: Biomed Testing Facility #BIO-20-98105, Seattle, Washington
Conditions: Rett Syndrome
Register for Updates
Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age
NCT06524882
Recruiting
Participants eligible for the study will be randomly allocated (1:1:1) to receive either Luminopia dichoptic treatment while wearing optical correction if needed, Vivid Vision dichoptic treatment while wearing optical correction if needed, or continued optical correction alone if needed, with clinical assessments at 9- and 18-weeks post-randomization. At the 18-week primary outcome visit, participants who were randomly assigned to receive optical correction alone if needed with an IOD of 1 logM... Read More
Gender:
ALL
Ages:
Between 8 years and 12 years
Trial Updated:
06/09/2025
Locations: Spokane Eye Clinical Research, Spokane, Washington
Conditions: Amblyopia
Register for Updates
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
NCT06380517
Recruiting
In children 4 to 7 years of age, to determine if treatment with 1 hour per day 6 days per week of watching dichoptic movies/shows wearing the Luminopia headset is non-inferior to treatment with 2 hours of patching per day 7 days per week with respect to change in amblyopic eye distance VA from randomization to 26 weeks.
Gender:
ALL
Ages:
Between 4 years and 7 years
Trial Updated:
06/09/2025
Locations: Seattle Children's Hospital, University of Washington, Seattle, Washington
Conditions: Amblyopia
Register for Updates
Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial
NCT06216899
Recruiting
This study will compare the tolerability and efficacy of conventional formula Exclusive Enteral Nutrition (EEN) and whole-food blended smoothie EEN by enrolling a total of 60 participants with newly diagnosed pediatric Crohn's disease (CD). Participants will be provided either commercial formula or guided on the preparation of the home-blended smoothie. These participants will be given a specific recipe, blender, and be provided the food components to the smoothie. The study will total 8 weeks... Read More
Gender:
ALL
Ages:
Between 8 years and 21 years
Trial Updated:
06/09/2025
Locations: Seattle Children's Hospital, Seattle, Washington
Conditions: Crohn Disease
Register for Updates
Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)
NCT05743244
Recruiting
A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.
Gender:
ALL
Ages:
Between 12 years and 35 years
Trial Updated:
06/09/2025
Locations: Benaroya Research Institute, Seattle, Washington
Conditions: Diabetes Mellitus, Type 1
Register for Updates
Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma
NCT05455697
Recruiting
This phase I/II trial tests the safety of tafasitamab, retifanlimab, and rituximab (TRR) as a prephase treatment and in combination with standard therapy consisting off cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or polatuzumab vedotin, cyclophosphamide, doxorubicin, and prednisone (PolaCHP) in patients with untreated diffuse large B-cell lymphoma. Tafasitamab, retifanlimab, and rituximab are monoclonal antibodies. Tafasitamab binds to a protein called CD19, which is found... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/09/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
Register for Updates